Treatment progress of diffuse large B-cell lymphoma / 白血病·淋巴瘤

ABSTRACT

Diffuse large B-cell lymphoma (DLBCL) is the most common malignant lymphoma subtype. Although the R-CHOP standard treatment regimen improved the overall survival of DLBCL patients, the 5-year overall survival rate of high-risk patients was still less than 50％. DLBCL is always a hot spot for research and attention. For example, the combination of new drugs, immune-targeted therapy with chimeric antigen receptor T cells or antibody therapy, how to reduce the long-term adverse and the search for new prognostic biomarkers and typing systems. The recent progress of DLBCL reported in the 60th American Society of Hematology Annual Meeting is briefly introduced in this paper.